These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 22877427)

  • 21. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parathyroid hormone as an anabolic skeletal therapy.
    Rubin MR; Bilezikian JP
    Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
    Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
    Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
    Lyritis GP; Georgoulas T; Zafeiris CP
    Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
    Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
    Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
    J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.
    Liu J; Laster A; Xu X; Guo H; Oates M; Gandra SR
    J Bone Miner Res; 2021 Dec; 36(12):2309-2316. PubMed ID: 34490946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A
    Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
    Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
    Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
    Skiba K; Adamczak M; Wiecek A
    Przegl Lek; 2011; 68(7):391-5. PubMed ID: 22010479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Up-to-date treatments for osteoporosis].
    Bors K
    Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches.
    Cosman F
    Curr Osteoporos Rep; 2014 Dec; 12(4):385-95. PubMed ID: 25341476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
    Miller PD; Delmas PD; Lindsay R; Watts NB; Luckey M; Adachi J; Saag K; Greenspan SL; Seeman E; Boonen S; Meeves S; Lang TF; Bilezikian JP;
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3785-93. PubMed ID: 18682511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of osteoanabolic therapy: a decade of experience.
    Cipriani C; Irani D; Bilezikian JP
    J Bone Miner Res; 2012 Dec; 27(12):2419-28. PubMed ID: 23165426
    [No Abstract]   [Full Text] [Related]  

  • 38. Teriparatide in the treatment of osteoporosis.
    Stroup J; Kane MP; Abu-Baker AM
    Am J Health Syst Pharm; 2008 Mar; 65(6):532-9. PubMed ID: 18319498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H; Hamaya E; Yamamoto T
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Rossi CM; Di Comite G
    N Engl J Med; 2008 Mar; 358(12):1302; author reply 1303-4. PubMed ID: 18354112
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.